Antibiotic Resistance Market anticipated to Witness High Growth owing to Increasing Prevalence of Infectious Diseases
Global Antibiotic Resistance Market |
The
global antibiotic resistance market is estimated to be valued at US$ 8.83 billion in 2024 and is
expected to exhibit a CAGR of 5.4%
over the forecast period from 2024 to
2031. Antibiotics are medicines used to prevent and treat bacterial
infections. However, with time, bacteria develop the ability to defend and
defeat the antibiotics. This ability to defeat antibiotics is known as
antibiotic resistance. The excessive and inappropriate use of antibiotics has
given rise to antibiotic-resistant bacteria. Resistance arises due to changes
or mutations that occur in the DNA of bacteria. As a result, antibiotics that
were once capable of killing bacteria become ineffective.
There is a growing need to tackle antibiotic resistance as the number of
antibiotic-resistant infections keeps increasing every year. Some of the most
common antibiotic-resistant bacterial infections include methicillin-resistant
Staphylococcus aureus (MRSA), Vancomycin-resistant enterococci (VRE),
drug-resistant tuberculosis, and gonorrhea. The rising cases of infectious
diseases and growing awareness about antibiotic resistance are driving the
growth of this market. The increasing number of surgical procedures are also
raising the need for newer antibiotics to treat and prevent postoperative
infections.
Key Takeaways
Key players operating in the Global
Antibiotic Resistance Market Demand are Melinta Therapeutics, Merck
& Co., Inc., Allergan, Pfizer Inc., Tetraphase Pharmaceutical, Inc.,
Theravance Biopharma, WOCKHARDT, Entasis Threapeutics, Paratek Pharmaceuticals,
Inc., Seres Therapeutics, Achaogen Inc., Basilea Pharmaceutical Ltd., Nabriva
Threapeutics plc, and NEMESIS BIOSCIENCE LTD. Majority of these players are
focusing on R&D activities to develop newer drugs to combat antibiotic
resistance. For instance, in 2021, Melinta Therapeutics received FDA approval
for its carbapenem antibiotic launch Vabomere.
The global market presents significant growth opportunities, especially in
developing countries where prevalence of infectious diseases is high. Key
opportunities include demand for antibiotics from hospital acquired infections,
rising research on phage therapy, approval of combination therapy, and
government support towards antibiotic development. Geographically, the Asia
Pacific region is anticipated to be the fastest growing market owing to large
patient pool and improving healthcare infrastructure.
Market Drivers and Restrain
Market Drivers
Growing prevalence of infectious diseases globally is a key driver. From
2000 to 2015, infectious diseases claimed roughly 41 million lives annually.
Diseases like COVID-19, tuberculosis, pneumonia, and lower respiratory
infections are majorly contributing to antibiotic resistance. With rising cases
of such infections, the demand for novel antibiotics is increasing.
Increasing funding for R&D of novel drugs is boosting the market growth.
Both government and private organizations are funding research activities for
development of new antibiotic classes to overcome resistance. For instance, US
government launched CARB-X program in 2016 with initial funding of US$ 456
million for supporting global non-profit partners in antibacterial research.
Market Restrain
High costs associated with developing new antibiotics is a major challenge.
It takes around US$ 1-2 billion and 10-15 years to develop a novel antibiotic.
Moreover, strict drug approval regulations make the whole process lengthy and
costly. This deters pharmaceutical companies from investing in this area.
Segment Analysis
The global antibiotic resistance market is dominated
by the cephalosporin sub-segment and held a market share of around 30% in 2024.
Cephalosporins are one of the most commonly prescribed classes of antibiotics
due to their broad spectrum of activity and favorable safety profile. They are
effective against both gram-positive and gram-negative bacteria, making them
useful for treating a wide range of bacterial infections like pneumonia, skin
infections, ear infections, and urinary tract infections. The increasing
prevalence of bacterial resistance to cephalosporins like methicillin-resistant
Staphylococcus aureus (MRSA) is boosting the demand for new and more effective
antibiotic treatments.
Global Analysis
North America dominated the global antibiotic resistance market in 2024 and
is expected to maintain its dominance over the forecast period. This is
attributed to high healthcare spending, growing research on novel drug
development, and the presence of key pharmaceutical companies conducting
clinical trials for antibiotic resistance in the region. Europe held the second
largest market share and is anticipated to witness significant growth owing to
supportive government funding for antibiotic resistance related research
projects. The Asia Pacific region is projected to be the fastest growing market
during the forecast period due to the rising burden of infectious diseases,
growing awareness about antibiotic resistance, and improving healthcare
infrastructure across developing nations.
Get more insights on Antibiotic
Resistance Market
Comments
Post a Comment